Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Intrahepatic cholangiocarcinoma, drawn from the whole corpus: 87 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Most patients present unresectable, and recurrence after resection is common.
Nothing recorded yet.
Also on OnCo: Treatment journeys · Survivorship planner.
FGFR inhibitor resistance develops within a year through kinase domain mutations.
Also on OnCo: Resistance atlas · Lines of therapy.
Rising incidence in Western countries without a clear cause.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 19 changes by month →When this page itself was last checked or edited.
OS 14.
3-year overall survival 77.
Confirmed ORR by independent central review 41.
OS 12.
A milestone in how this cancer is treated.